by François Briand | Apr 4, 2022 | 2022
Physiogenex will be presenting a poster at the Keystone Symposia – Lessons from the pandemic to be held in Snowbird, UT, USA on April 10th-13th. The poster entitled “Diet-induced obesity and NASH aggravate SARS-CoV-2 infection in golden Syrian...
by François Briand | Mar 29, 2022 | 2022
Physiogenex will be presenting an e-Poster at the 31st conference of the Asian Pacific Association for the Study of Liver (APASL) to be held in Seoul, Korea and virtually on March 30th – April 3rd 2022. The presentation title is “SEMAGLUTIDE AND...
by François Briand | Mar 17, 2022 | 2022
Physiogenex invites you to attend its new webinar presented by our expert Dr. François Briand on Thursday, March the 17th 2022 at 5pm CET, 11am EST, 8am PST: Optimize your drug development with novel animal models of human nonalcoholic steatohepatitis Register here...
by François Briand | Jan 19, 2022 | 2022
François Briand, Director of Research and Business Development at Physiogenex, will be giving a talk during the HFpEF Drug Discovery & Development Summit 2022, a digital event, on Wednesday, January 26, 2022, 18:30 CET time / 12.30 EST time / 9:30 PT time. The...
by François Briand | Jan 1, 2022 | 2022
Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model on January 6th-8th, 2022 at the NASH-TAG 2022 conference in Park City, UT, USA. Meet Dr François Briand, our Director of...
